Prothrombin Fragment 1+2 MoAb
Use
The Prothrombin Fragment 1+2 MoAb test is used to measure the levels of prothrombin fragment 1+2 in plasma. This biochemical marker is released upon the activation of coagulation and can be an indicator of thrombin generation in vivo. It is often used to assess thrombotic conditions and help in diagnosing conditions associated with increased blood clotting activities, such as deep vein thrombosis, pulmonary embolism, and disseminated intravascular coagulation.
Special Instructions
Not provided.
Limitations
The Prothrombin Fragment 1+2 MoAb test is dependent on the specimen being correctly collected and processed. Improper handling can lead to rejection of the specimen and delays in diagnosis. Specimens that are not plasma or use anticoagulants other than sodium citrate will be rejected. Additionally, pre-analytical conditions, such as a difficult draw, may spuriously increase test results, potentially affecting the accuracy of the test.
New York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
Prothrombin Fragment 1+2
Analyte
LOINC Codes
- 27824-2 - Pro Frg1+2 Ag SerPl IA-sCnc
- 27824-2 - Pro Frg1+2 Ag SerPl IA-sCnc
Result Turnaround Time
5-13 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
2 mL
Minimum Volume
1 mL
Container
Light-blue top (citrate)
Collection Instructions
Draw blood in a light blue-top (Sodium citrate) tube(s). Centrifuge and aliquot 2 mL citrated plasma into a plastic vial. Send frozen.
Patient Preparation
Do not draw from an arm with a heparin lock or heparinized catheter.
Causes for Rejection
Specimens other than Plasma, Anticoagulants other than sodium citrate
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | 365 days |